Genmab Gains, Sabadell Rises, Vend Tumbles

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Genmab and AbbVie’s epcoritamab & R-CHOP combination for Diffuse large B-cell lymphoma cut the risk of disease progression or death by 51%, according to phase 3 topline data. Analysts say the positive results help de-risk sales expectations, with progression-free survival rate ahead of expected bar.
- BPCE acquired a stake of about 7% in Spain’s Banco Sabadell SA as Chief Executive Officer Nicolas Namias seeks to expand business outside the French home market.
- Vend Marketplaces shares fall as much as 9.7% as Nordea analysts downgrade the stock to sell from buy on the risk that consumers using AI agents to access inventory could cause the classifieds platform to lose control of traffic and monetization.

See omnystudio.com/listener for privacy information.